Slingshot members are tracking this event:
Amgen (AMGN) and UCB Announce Phase III FRAME Results Evaluating Romosozumab in Postmenopausal Women with Osteoporosis
Slingshot Insights Explained
Sep 18, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase Iiii Frame Results, Romosozumab, Postmenopausal Women, Osteporosis